Celldex Therapeutics
CLDX
45 hedge funds and large institutions have $7.15M invested in Celldex Therapeutics in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 8 closing their positions.
286% more call options, than puts
Call options by funds: $220K | Put options by funds: $57K
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.18% less ownership
Funds ownership: 23.76% → 22.58% (-1.2%)
6% less funds holding
Funds holding: 48 → 45 (-3)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
24% less capital invested
Capital invested by funds: $9.42M → $7.15M (-$2.26M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$124K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$114K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$79.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$49.3K |
| 5 |
MCP
Mirador Capital Partners
Pleasanton,
California
|
+$25.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$88K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$64.5K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$61.2K |
| 4 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
-$56K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$48K |
CLDX Hedge Fund Activity: Q1 2020 in Review
45 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2020, worth a combined $7.15M — down 24% from $9.42M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of CLDX and 7 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 10 added.
The largest buyer was Renaissance Technologies, adding an estimated $124K. The largest seller was Invesco, exiting entirely with an estimated $88K sold.
- 45 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2020, down from 48 in Q4 2019.
- Funds reported $7.15M of Celldex Therapeutics stock for Q1 2020, down 24% quarter-over-quarter.
- 7 funds opened new Celldex Therapeutics positions in Q1 2020 and 8 closed out, a net change of -1 holder.
- The largest Celldex Therapeutics buyer in Q1 2020 was Renaissance Technologies, an estimated $124K added.
- The largest Celldex Therapeutics seller in Q1 2020 was Invesco, an estimated $88K sold.
Based on aggregated 13F filings for Q1 2020.